drugset / Trial / NCT06199505

A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM

NCT06199505

Phase 2 Completed 153 enrolled Gan and Lee Pharmaceuticals, USA
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in China. The aim of the trial is to compare the efficacy and safety of GZR101 and insulin degludec/insulin aspart in insulin naïve or insulin treated subjects with type 2 diabetes.

Timeline

Start
2023-11-21
Primary completion
2024-06-28
Completion
2024-07-12

Drugs

EvaluationDrugModalityDoseRoute
Subject GZR101 Unknown Subcutaneous
Comparator insulin degludec/insulin aspart Unknown Subcutaneous